NM_000179.3:c.2300C>T
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PP3_StrongPP5_Very_Strong
The NM_000179.3(MSH6):c.2300C>T(p.Thr767Ile) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000479 in 1,461,870 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★).
Frequency
Consequence
NM_000179.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1461870Hom.: 0 Cov.: 34 AF XY: 0.00000550 AC XY: 4AN XY: 727234
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:3
This missense variant replaces threonine with isoleucine at codon 767 of the MSH6 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). A functional study has shown that this variant results in a significant decrease in mismatch repair activity compared to wild type MSH6 protein (PMID: 31965077). This variant has been reported in individuals affected with endometrial, uterine, and colorectal cancers (PMID: 29755653, 31100584, 33467402; ClinVar SCV000184163.7), and it has been shown that this variant segregates with disease in one family (PMID: 31100584). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic. -
- -
The p.T767I pathogenic mutation (also known as c.2300C>T), located in coding exon 4 of the MSH6 gene, results from a C to T substitution at nucleotide position 2300. The threonine at codon 767 is replaced by isoleucine, an amino acid with similar properties. This alteration was identified in several individuals whose Lynch-related tumors demonstrated high microsatellite instability and/or demonstrated loss of MSH6 expression on immunohistochemistry (IHC) and family history meets Amsterdam criteria (Ambry internal data; Fokkema IF et al. Hum. Mutat., 2011 May;32:557-63; Stembalska A et al. Eur. J. Obstet. Gynecol. Reprod. Biol., 2019 Jul;238:54-57). This alteration is also present in five first degree female relatives diagnosed with endometrial cancer (Stembalska A et al. Eur. J. Obstet. Gynecol. Reprod. Biol., 2019 Jul;238:54-57). In one in vitro complementation assay, mismatch repair activity for this variant was similar to that of the pathogenic control (Drost M et al. Genet Med, 2020 05;22:847-856). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Lynch syndrome 5 Pathogenic:1Uncertain:1
This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function. This variant is expected to disrupt protein structure [Myriad internal data]. -
- -
Carcinoma of colon Pathogenic:1
The MSH6 p.Thr767Ile variant was identified in the literature found in patient with clear cell carcinoma of the uterus and absence of MSH6 protein and presence of protein for MLH1, MSH2 and PMS2 on IHC (Gray 2018), found in patient in second recurrence heterogeneously enhancing infiltrating tumor (Erson-Omay 2017) and in an endometrial cancer patient with isolated loss of MSH6 in tumour (McGill University Health Centre personal communication). In addition, the variant was identified in our laboratory in one family with segregation in 3 individuals. The variant was also identified in dbSNP (ID: rs587781462) as "With Pathogenic, Uncertain significance allele", ClinVar (classified as pathogenic by InSight; as likely pathogenic by Ambry Genetics; as uncertain significance by Invitae, Counsyl and COGR). The variant was not identified in UMD-LSDB. The variant was not identified in the following control databases: the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). The p.Thr767 residue is conserved across mammals and other organisms, and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more pathogenic role for this variant. This variant is classified as likely pathogenic. -
Hereditary nonpolyposis colon cancer Pathogenic:1
Variant summary: MSH6 c.2300C>T (p.Thr767Ile) results in a non-conservative amino acid change located in the core domain (IPR007696) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251156 control chromosomes (gnomAD). c.2300C>T has been reported in the literature in individuals affected with endometrial cancer (example: Adar_2018, Stembalska_2019, and Lawrence_2021). In one family, this variant has been reported to segregate with the disease (Stembalska_2019). These data indicate that the variant is very likely to be associated with disease. In functional in vitro studies, the variant was found to have reduced mismatch repair (MMR) activity (Drost_2020). Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as VUS (n=2) and pathogenic/likely pathogenic (n=5). Based on the evidence outlined above, the variant was classified as pathogenic. -
Lynch syndrome 1 Pathogenic:1
Class 5 - Pathogenic Classification using multifactorial probability: 0.993 -
Rhabdomyosarcoma Pathogenic:1
- -
not provided Pathogenic:1
Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies demonstrate reduced in vitro mismatch repair activity compared to wild type (PMID: 31965077); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 28153049, 21520333, 33372952, 17531815, 21120944, 31100584, 29755653, 33281875, 33467402, 30128536, 31965077, 29750335) -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change replaces threonine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 767 of the MSH6 protein (p.Thr767Ile). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of Lynch syndrome (PMID: 29755653, 31100584). It has also been observed to segregate with disease in related individuals. Invitae Evidence Modeling of clinical and family history, age, sex, and reported ancestry of multiple individuals with this MSH6 variant has been performed. This variant is expected to be pathogenic with a positive predictive value of at least 99%. This is a validated machine learning model that incorporates the clinical features of 1,370,736 individuals referred to our laboratory for MSH6 testing. ClinVar contains an entry for this variant (Variation ID: 141058). Invitae Evidence Modeling incorporating data from in vitro experimental studies (internal data) indicates that this missense variant is expected to disrupt MSH6 function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects MSH6 function (PMID: 31965077). For these reasons, this variant has been classified as Pathogenic. -
not specified Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at